Legend Biotech to Showcase Long-Term CARVYKTI Data at IMS Annual Meeting
Event summary
- Legend Biotech will present updated long-term follow-up data from the CARTITUDE-2 Cohort A trial at the 23rd International Myeloma Society Annual Meeting.
- Real-world evidence and post-authorization safety study findings for CARVYKTI will also be shared.
- The presentations will include data on patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy.
- The event takes place September 23-26, 2026, in Glasgow, Scotland.
The big picture
Legend Biotech's presentation at the IMS Annual Meeting underscores the growing importance of real-world evidence in cell therapy. The data could bolster CARVYKTI's standing as a leading treatment for relapsed/refractory multiple myeloma, particularly in earlier lines of therapy. The strategic focus on long-term outcomes aligns with broader industry trends toward demonstrating sustained efficacy and safety in oncology treatments.
What we're watching
- Clinical Efficacy
- How the long-term remission and survival data from CARTITUDE-2 will impact CARVYKTI's market positioning.
- Regulatory Dynamics
- Whether the real-world evidence and safety study findings will influence future regulatory approvals or label expansions.
- Competitive Landscape
- The pace at which Legend Biotech can differentiate CARVYKTI in the crowded multiple myeloma treatment space.
Related topics